ST Pharm Co Ltd
KOSDAQ:237690
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (59.3), the stock would be worth ₩40 058.16 (72% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 210 | ₩141 900 |
0%
|
| 3-Year Average | 59.3 | ₩40 058.16 |
-72%
|
| 5-Year Average | 128.3 | ₩86 672.44 |
-39%
|
| Industry Average | 25 | ₩16 903.28 |
-88%
|
| Country Average | 9 | ₩6 072.49 |
-96%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
2.9T KRW | 210 | 53.4 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 1 771.2 | 4 280.5 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
193.4B USD | 24.7 | 28.8 | |
| US |
|
Danaher Corp
NYSE:DHR
|
130.1B USD | 20.3 | 36 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 36.6 | 46.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
34.9B CHF | 29.4 | -123.8 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
296.1B CNY | 17.3 | 15.6 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.1B USD | 24.4 | 26.4 | |
| US |
|
Waters Corp
NYSE:WAT
|
32.8B USD | 50.3 | 51 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.7B USD | 11.2 | 22 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.7B USD | 27.9 | 30.7 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 4.2 |
| Median | 9 |
| 70th Percentile | 16.6 |
| Max | 2 215 132.4 |
Other Multiples
ST Pharm Co Ltd
Glance View
Nestled in the bustling metropolis of Seoul, South Korea, ST Pharm Co Ltd. operates as a dynamic player within the global pharmaceutical industry. Established initially to meet the burgeoning demands of the local pharmaceutical market, the company has slowly carved out a niche for itself in the global arena. With a deft focus on the development and manufacture of active pharmaceutical ingredients (APIs), ST Pharm now sets its sights on becoming a central figure in the synthesis of high-value APIs used in therapies including antivirals and oncology treatments. This focus isn't merely driven by opportunity; it's underpinned by a dedicated commitment to cutting-edge research and development. The company has invested heavily in state-of-the-art facilities and nurtures a team of seasoned scientists who remain at the forefront of innovation. ST Pharm makes its revenue by mastering the art of efficient and reliable API production. By optimizing their production processes, they can offer a competitive edge—delivering high-quality products at scale. The company isn't solely interested in the immediate gains of API manufacture; it also sees potential in providing customized solutions to its diverse clientele, which spans multinational pharmaceutical giants to nimble biotech startups. Partnerships and collaborations have become crucial strategies for ST Pharm, facilitating an exchange of innovation and expertise that keeps them relevant and forward-thinking. In this regard, their business model elegantly balances between standardized API production and bespoke chemical solutions, ensuring a steady revenue stream while opening doors to future advancements in pharmaceutical science.